Alethio Raises $90M to Target Rare Blood Cancers

Alethio raises $90M to target rare blood cancers

The startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.

Alethio Therapeutics Raises $90 Million Series A | Cooley // Cooley // Global Law Firm

London – November 5, 2026 – Cooley advised Alethio Therapeutics, a biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms, on its $90 million Series A. Lawyers Tom Goodman, Joe Sandys, Ellen Dewhurst and Alexandra Paterson led the Cooley team advising Alethio Therapeutics.

Oxford spinout Alethio clinches $90M to advance antibody for rare blood cancer

About a year after emerging from stealth, University of Oxford spinout Alethio Therapeutics has collected $90 million in a Series A raise to support its lead rare blood cancer program. The ...

Oxford spinout Alethio raises $90M Series A for chronic blood cancer trials - European Biotechnology Magazine

University of Oxford spinout Alethio Therapeutics has raised $90 million (about €80 million) to take its G6B-targeting antibody ATX-011 into clinical trials for essential thrombocythemia. The proceeds will fund ATX-011 through Phase 1/2a studies, with the goal of preparing it for Phase 3 development, while advancing additional programs toward applications to begin clinical trials.